JAN 09, 2018 6:17 AM PST

Something Else for Beta Blockers to Do: Treat Melanoma

WRITTEN BY: Kara Marker

A drug used to lower blood pressure and prevent heart attacks could also be used to treat melanoma. From Penn State, researchers are studying how a specific type of beta blocker - widely available and approved by the FDA - can improve the effectiveness of cancer immunotherapy for melanoma patients whose cancer has spread to different tissues in the body.

Credit: Penn State / © iStock Photo / digicomphoto

Beta blockers reduce blood pressure by opening up blood vessels to improve blood flow and prevent heart attacks by inhibiting the effects of epinephrine, a hormone also called adrenaline. Pan beta blockers are commonly known to be safe, which means that they could be more quickly applied to melanoma patients than a newly developed drug. In theory, beta blockers are able to lower stress to empower the immune system to fight cancer on its own.

"Most patients are either prescribed beta-1 selective blockers or are not taking beta blockers at all,” explained Dr. Todd Schell. “This means there's a large population of patients who may be eligible to take pan beta blockers while being treated with immunotherapy.”

Metastatic melanoma patients receiving immunotherapy may have the best chance at living longer, although even with the treatment the response rates are low - less than 35 percent. “How can we make these treatments better?” asked Penn State’s Dr. Joseph Drabick.

"Beta blockers slow your heart rhythm, but they can also affect immune cells and improve immune function," Schell said. "We wanted to see if there would be a correlation between the beta blockers patients were taking for another condition and their response to immunotherapy.”

The new Penn State study involved giving beta blockers to melanoma patients receiving cancer immunotherapy as opposed to just immunotherapy. Of 195 metastatic melanoma patients being treated with immunotherapy, 62 were also taking beta blockers. Schell, Drabick, and the other researchers compared survival between patients taking two different kinds of beta blockers, beta 1-selective and pan beta blockers, and patients taking no beta blockers at all.

The results showed that patients taking pan beta blockers were significantly more likely to survive (70 percent alive after five years of immunotherapy) than patients taking beta 1-selective beta blockers or no beta blockers at all (25 percent). Researchers completed virtually the same study again, this time in mice with melanoma. Like the human trial, the mice were receiving immunotherapy with or without additional treatment of pan beta blockers. Immunotherapy plus pan beta blockers delayed tumor growth and increased survival.

“We saw that for patients taking pan beta blockers, there was a dramatic improvement in survival, and we were able to duplicate these findings in mice and see the exact same phenomenon,” Drabick explained.

Going forward, the Penn State researchers will continue their study on using beta blockers to improve immunotherapy to potentially treat a variety of cancers.

The present study was published in the journal OncoImmunology.

Sources: MayoClinic, Penn State

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
OCT 23, 2019
Immunology
OCT 23, 2019
Treating Celiac Disease May Be Possible
Delivering gluten to the body in a friendly, harmless package may be the way for people with celiac disease to finally have a sandwich again. A new clinica...
DEC 16, 2019
Drug Discovery & Development
DEC 16, 2019
Vaccine To Protect Against The Zika Virus
Scientists at The University of Texas Medical Branch at Galveston present for the first time how a single high dose vaccine can protect a pregnant mouse al...
DEC 20, 2019
Neuroscience
DEC 20, 2019
Does Having Herpes Increase Your Risk for Alzheimer's?
Around 44 million people around the world have Alzheimer’s disease, a progressive form of dementia that leads to memory loss and a decline in cogniti...
JAN 14, 2020
Clinical & Molecular DX
JAN 14, 2020
Can I eat this donut? A quick test for celiac disease.
Genetic testing revealed that our ancestors have been eating wheat, rye, spelt and barley for over 8,000 years. Today, gluten, a protein found within these...
MAR 09, 2020
Immunology
MAR 09, 2020
Mobilizing the brain's immune cells boosts memory
A study by researchers at Australia’s RMIT University has uncovered a surprising connection between immune cells in the brain and their influence on...
MAR 23, 2020
Drug Discovery & Development
MAR 23, 2020
Top 5 Candidates for Coronavirus Vaccine Around the World
It’s easy to complain about the role of big pharma in medicine-making and the hassle of dealing with protective patents when combating various diseas...
Loading Comments...